Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology
Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Ginkgo Bioworks Stock Is Rallying Tuesday: Here's Why
Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology
Ginkgo Bioworks Executive Sells Over $1,900 in Stock
Is Ginkgo Bioworks Holdings, Inc. (DNA) A Good High Risk High Reward Growth Stock To Buy?
Ginkgo Bioworks Awarded $118M U.S. Government HHS Contract
Ginkgo Regains Compliance With NYSE Minimum Bid Price Requirement
NYSE to Commence Delisting Proceedings With Respect to the Warrants of Ginkgo Bioworks Holdings, Inc. (DNA.WS)
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
Stocks Hitting All-time Highs: JPM, KO, LMT, UNH, and More
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $7
BTIG analyst Mark Massaro maintains $Ginkgo Bioworks(DNA.US)$ with a sell rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 31.4% and a total
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
BTIG Maintains Sell on Ginkgo Bioworks Holdings, Adjusts Price Target To $7 (1-40 Reverse Stock Split)
Ginkgo Bioworks Holdings Analyst Ratings
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $7
BTIG analyst Mark Massaro maintains $Ginkgo Bioworks(DNA.US)$ with a sell rating, and adjusts the target price from $8 to $7.According to TipRanks data, the analyst has a success rate of 31.4% and a
Ginkgo Bioworks Holdings: Sell Rating Affirmed With Revised Valuation and Price Target
Express News | Ginkgo Bioworks Holdings Inc : Btig Adjusts Target Price to $7 From $0.2 to Reflect 1-for-40 Reverse Stock Split
Why We're Not Concerned Yet About Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 31% Share Price Plunge